When Coverage Runs Out: The Coverage Gap Driving American Retirees to Canadian Pharmacies
Photo: bluesbby from Mountain View, USA, CC BY 2.0, via Wikimedia Commons
Every January, millions of American retirees begin the year with a sense of relief. Their Medicare Part D prescription drug coverage has reset, their copays are manageable, and their monthly budgets feel, briefly, under control. Then, somewhere in the autumn months, that relief evaporates. The plan stops paying its full share, out-of-pocket costs climb sharply, and a bottle of medication that cost forty dollars in June can cost four hundred by October.
This is the coverage gap — known colloquially as the 'donut hole' — and it remains one of the most consequential quirks in American health policy. For a growing number of retirees on fixed incomes, the response has been to look beyond the U.S. border, where the same molecules are sold at a fraction of the price.
Why the Gap Exists at All
Medicare Part D is administered by private insurers but shaped by federal rules. Under the benefit design, beneficiaries move through distinct phases of cost-sharing across the year: a deductible, an initial coverage period, and — historically — a gap in which beneficiaries shouldered a much larger share of drug costs.
The Inflation Reduction Act of 2022 narrowed the donut hole considerably, capping annual out-of-pocket spending beginning in 2025. Yet the structural problem endures: even with the cap, many seniors hit that limit well before year's end, particularly those taking brand-name medications for diabetes, heart disease, or cancer. Once the cap is reached, some beneficiaries qualify for catastrophic coverage — but the spending required to get there can consume a retiree's entire discretionary income.
The Arithmetic of a Fixed Income
Consider a representative scenario. A retired schoolteacher in Ohio taking a brand-name anticoagulant might pay roughly $500 per month at an American pharmacy without meaningful coverage. The identical product, dispensed from a licensed Canadian pharmacy, commonly retails between $80 and $150 per month. Over a year, the difference approaches $4,000 — money that, for someone living on Social Security, is not discretionary.
The reasons for this disparity are well documented. Canada's Patented Medicine Prices Review Board regulates the introductory prices of new patented drugs, and provincial drug programs negotiate collectively on behalf of their populations. The United States, by contrast, permits manufacturers to set prices largely without constraint, and until recently prohibited Medicare from negotiating directly.
Legality and Safety: What Retirees Should Understand
The legal landscape around personal drug importation is narrower than many assume. Under longstanding federal guidance, individuals may generally import a personal supply of a prescription medication for their own use, provided it is a 90-day supply or less, the drug is not a controlled substance, and the patient holds a valid prescription from a licensed provider. Enforcement against individual consumers importing for personal use has historically been rare.
Safety, however, depends entirely on sourcing. Health Canada regulates Canadian pharmacies under a system comparable in rigour to the FDA's, but not every website claiming to be Canadian operates in Canada — or sells genuine medication. Retirees should verify that a pharmacy is licensed by a Canadian provincial regulatory authority, requires a valid prescription, and displays a physical Canadian address and licensed pharmacist contact.
A Policy Question That Refuses to Go Away
Drug pricing experts remain divided on whether personal importation is a solution or a symptom. Critics argue it is a workaround that leaves consumers exposed to counterfeit risk; defenders counter that it is a rational market response to a pricing system that charges Americans more than any other wealthy nation for identical products.
What is not disputed is the direction of the trend. As long as the price differential persists — and current analyses suggest it will for years — retirees navigating the coverage gap will continue to do the arithmetic, and a growing share will conclude that a licensed Canadian pharmacy offers the same medicine at a price their budget can survive.
